Timolol
As of the edition of 20 October 2026, Timolol is a small molecule: marketed, first approved in 1978 (FR); acts on ADRB1 and ADRB2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Small molecule
- Brand name
- Blocadren
- First approved
- 22 May 1978 (FR)
- Approvals on record
- 45 in 7 regions
- Holder of the most recent approval
- Thea Pharma; 15 holders in all
- Registered trials
- 127, 16 stopped early
- Disease areas
- Eye; Cancer; Heart and blood vessels; Skin and connective tissue; Inherited and neonatal; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product5 company-target rows are on route B because of Timolol.
See the 5 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 25 | 18 | 2 | 2 |
| Phase 1 | 12 | 7 | 2 | 3 |
| Phase 2 | 19 | 12 | 2 | 3 |
| Phase 3 | 32 | 29 | 0 | 3 |
| Phase 4 | 39 | 30 | 1 | 5 |
| All trials | 127 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Santen Pharmaceutical | Applicant and Lead sponsor of trials | 1978 to now |
| Santen | Later holder and Lead sponsor of trials | 1995 to now |
| Alcon | Later holder and Lead sponsor of trials | 1998 to now |
| Sandoz | Later holder | 1998 to now |
| AbbVie | Applicant, Later holder and Lead sponsor of trials | 2003 to now |
| Merck & Co. | Applicant and Lead sponsor of trials | 2005 to now |
| Pfizer | Applicant and Lead sponsor of trials | 2005 to now |
| Novartis | Applicant and Later holder | 2006 to now |
| Senju Pharmaceutical | Later holder | 2019 to now |
| Thea Pharma | Acquired holder | 2022 to now |
| Bausch Health | Acquired holder | 2022 to now |